Tuesday, July 31, 2012

Clean Energy Stock News: Clean Wind Energy Tower, Inc. (OTCBB:CWET) Letter to Shareholders

Annapolis, MD - July 31, 2012 (Investorideas.com renewable energy/green newswire) Clean Wind Energy Tower, Inc. (OTCBB:CWET) (the "Company") announced that the Company had communicated to their shareholders of record in a letter that stated:

July 31, 2012
To our valued shareholders,
The executive team at Clean Wind Energy Tower, Inc. has been busy pressing forward to monetize our valuable research, proprietary data and Intellectual Property. Last week we announced that our "Core Patent" had been issued and we believe this provides us with a distinct business advantage over any potential competitor in the development of the first Energy Downdraft Tower.
Our principal goal had been to secure a site and obtain all of the necessary entitlements to develop the first Energy Downdraft Tower. We recently announced that the City of San Luis, Arizona unanimously approved the zoning on a parcel of land in San Luis to host our first Tower. Simultaneously, San Luis approved zoning to allow construction of a manufacturing facility at the same location for the assembly of the Tower's wall sections. Our company also has entered into a separate Development Rights Agreement with San Luis to further support the addition of a second Tower on a neighboring property.
Perhaps the most exciting new development comes from the very recent weather data models recently completed by our consultants. It has always been our intention to develop the first Energy Downdraft Tower as inexpensively as possible, while preserving pro forma net cash flows after operations of at least twice that amount required to service the accompanying debt. Actual atmospheric data from the San Luis Tower location area now confirms that we can lower the first Tower height from 3,000 feet down to 2,250 feet without compromising our goal of maintaining 2:1 cash flow coverage for debt service. This modification significantly reduces risk, costs, and construction time as well as water consumption.
In closing, we have certainly come a long way towards achieving our intended goal of developing the first Energy Downdraft Tower. We are rapidly approaching that "turning point "when all that will be needed is sufficient capital to actually construct the first tower. Our objective is to obtain that necessary project capital through partnerships for each Tower. Until then, we will continue to seek to finance our early stage development activities through the public company.
Thank you for your continued support!
Sincerely,
Ronald W. Pickett, President & CEO
Clean Wind Energy Tower, Inc.
About Clean Wind Energy, Inc.
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., has designed and is preparing to develop, and construct large "Downdraft Towers" that use benevolent, non-toxic natural elements to generate electricity and clean water economically by integrating and synthesizing numerous proven as well as emerging technologies.
The Company's core objective and focus is to become a provider of clean efficient green energy to the world communities at a reasonable cost without the destructive residuals of fossil fuel, and to help broker the chasm between both, while continuing to generate innovative technological solutions for today and tomorrow's electrical power needs. In addition to constructing Downdraft Towers in the United States and abroad, the Company intends to establish partnerships at home and abroad to propagate these systems and meet increasing global demand for clean water and electricity. Clean Wind has assembled a team of experienced business professionals, engineers and scientists with access to the breakthrough energy research upon which this technology is founded and the proven ability to bring the idea to market. Clean Wind Energy, Inc. has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Clean Wind Energy, Inc. is based in Annapolis MD, and is traded on the OTCBB under the symbol 'CWET'. For more information visit www.cleanwindenergytower.com
Clean Wind has filed several patents that the Company believes will further enhance this potentially revolutionary technology. Clean Wind Energy, Inc. is based in Annapolis MD, and is traded on the OTCBB under the symbol 'CWET'. For more information, please visit www.cleanwindenergytower.com.
Contact:
Clean Wind Energy, Inc.
1997 Annapolis Exchange Parkway Suite 300
Annapolis, Maryland 21401
Phone: 410-972-4713
E-mail: Info@cwetower.com
www.cleanwindenergytower.com
Investor Relations Contact:
Jody Janson
Phone: (855) 848-6937
Email: ir@cwetower.com
Cautionary Note Regarding Forward-Looking Statements
Statements included in this release may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Company's financial results, can be found in the Company's various filings with the Securities and Exchange Commission (SEC).
Visit the CWET showcase page at Investorideas.com:
http://www.investorideas.com/CO/CWE/
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) publishing program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand per month to publish news and updates on the company on Investorideas.com newswire and blogs . Investorideas.com owns 150,000 shares of 144 stock .Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Closes up over 13%

New York, NY - July 31, 2012 - (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveIDCorporation (OTCBB: PSID), following recent news and developments for its M-BAND System for biothreat detection.

The stock closed trading on July 30th at $0.0260, gaining $0.0030, or 13.04% on over 1.9 Million shares. The Company recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.
Investorideas.com Newswire Full news:
http://www.investorideas.com/CO/PSID/news/2012/07251.asp
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411

Monday, July 30, 2012

Healthcare Stocks: Comprehensive Care Corporation (OTC:CHCR) Retained by CHRISTUS Health to Provide Behavioral Health Management Services

TAMPA, Fla. - July 30, 2012 (Investorideas.com newswire) - Comprehensive Care Corporation ("CompCare" or the "Company") (OTCBB: CHCR), which provides behavioral health, substance abuse and psychotropic pharmacy management services for managed care companies throughout the U.S., is pleased to announce that it has been retained by CHRISTUS Health Plan (www.christushealthplan.org) to provide managed behavioral health services to the Medicaid (STAR) and Children's Health Insurance Program (CHIP) populations served in the Nueces Service area, which is comprised of fourteen counties in the Coastal Bend region of Texas.

This agreement is particularly important to CompCare as it is consistent with the Company's long-standing business strategy of being a prime provider of behavioral health services to Medicare, Medicaid and CHIP programs throughout the United States.
"New management has increased the number of states served by CompCare from eight states and Puerto Rico to 22 states, the District of Columbia and Puerto Rico," said Clark Marcus, CompCare Chairman and CEO. "This contract is an example of how we are continually growing CompCare for the ultimate benefit of our shareholders."
About CHRISTUS Spohn Health System
CHRISTUS Spohn Health System is the region's largest charity care provider and not-for-profit health care system consisting of six hospital campuses – CHRISTUS Spohn Hospital Corpus Christi (Shoreline, Memorial and South), CHRISTUS Spohn Hospital Alice, CHRISTUS Spohn Hospital Beeville and CHRISTUS Spohn Hospital Kleberg (Kingsville).
The health system is consistently ranked as a leading health system in the area and has received national recognition for several pioneering programs, including cardiac care, clinical excellence and oncology. For more than 100 years, CHRISTUS Spohn has been distinguished by its high caliber staff and affiliated physicians, its comprehensive and innovative services, and its long history of responding to the needs of the community it serves. For additional information, visit our website at www.christusspohn.org.
CHRISTUS Health Plan is a subsidiary of CHRISTUS Health delivering a broad range of health care services throughout Texas. CHRISTUS Health Plan combines the resources of physicians, multi-specialty groups, ambulatory care centers, ancillary providers and hospitals to offer members access to a comprehensive array of high quality health care.
About CompCare
Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States . Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release, including but not limited to our expected profitability in the second quarter of 2012, the continued implementation of our Pharmacy Management Program, the impact of the financial responsibility shift with one of our existing, at-risk pharmacy clients, our ability to increase margins and to obtain sustainable profitability, our ability to reduce overhead and implement further cost savings, our ability to further improve the Company's performance, the outcome of our business strategy, our ability to expand our pharmacy management program with higher profit margins, and our ability to reduce pharmacy expenses throughout the year are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new and existing business, our ability to expand and manage our provider network, the profitability, if any, of our recently acquired or previously existing capitated contracts, the costs incurred in seeking new contracts, the loss or termination of any existing contract, increases or variations in cost of care, seasonality, the Company's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
949.707.5365
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk. Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Investor News; Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

New York, New York - July 30, 2012 - Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues CFA commentary by Patrick J. Murphy of Murphy Analytics LLC on Sunshine Biopharma Inc. (OTCBB: SBFM) and its lead anti-cancer compound, Adva-27a.

Select Stock Trading Data
Recent Stock Price: $0.34
Shares Outstanding: 48.7 million
Float 13.9 million
Recent Market Cap: $16.8 million
52 Week Range: $0.12 - $1.45
Exchange: OTCBB
Ticker: SBFM
URL: http://www.sunshinebiopharma.com
Data sourced from Yahoo! Finance; otcbb.com; Company filings
Sunshine Bipharma, Inc. (SBFM) is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. SBFM reports that the preclinical studies for the Company's lead compound, Adva-27a, a multi-purpose anti-tumor compound, were successfully completed in late 2011. SBFM is now continuing the clinical development of Adva-27a by conducting the next sequence of steps comprised of GMP manufacturing, IND-enabling studies, regulatory filing and Phase I clinical trials. SBFM plans to conduct Phase I clinical trials for Adva-27a at the Jewish General Hospital, Montreal, Canada, one of McGill University's Hospital Centers.
The planned indication will be multidrug resistant breast cancer as SBFM reports that Adva-27a has shown remarkably strong cytotoxic activity against this type of cancer. In addition, on June 26, 2012, SBFM announced the completion of another cytotoxicity study in which Adva-27a was found to be significantly more effective at killing multidrug resistant small-cell lung cancer (SCLC) cells than etoposide, a drug commonly used currently for treating SCLC.
SBFM has licensed its technology on an exclusive basis from Advanomics Corporation and is planning to initiate its own research and development program as soon as practicable
An article in nature biotechnology summarizes the challenge multidrug resistance creates for developing effective treatments:
"Multidrug resistance, the principal mechanism by which many cancers develop resistance to chemotherapy drugs, is a major factor in the failure of many forms of chemotherapy. It affects patients with a variety of blood cancers and solid tumors, including breast, ovarian, lung, and lower gastrointestinal tract cancers. Tumors usually consist of mixed populations of malignant cells, some of which are drug-sensitive while others are drug-resistant. Chemotherapy kills drug-sensitive cells, but leaves behind a higher proportion of drug-resistant cells. As the tumor begins to grow again, chemotherapy may fail because the remaining tumor cells are now resistant."
As explained in an article published by the National Institutes of Health (NIH), this cellular response to toxins in the environment is critical for our survival and has evolved over time:
"Toxins in the environment are a major threat to many living organisms. Once internalized, toxic compounds must be removed for the organisms to survive. Therefore, humans have developed, inherited and perfected ways to reduce the effect of xenobiotics. At the cellular level, the cell membrane acts as a physical barrier to prevent compounds from entering the cell. However, because some compounds can diffuse through the cell membrane, alternative protective methods have evolved. One of the most important defense mechanisms is to pump xenobiotics out of the cells. Thus, drug transporters are commonly found in the cell membranes of many organisms, from bacteria to mammals, and are responsible for cell protection. However, the existence of these drug transporters often hinders the use of compounds used to treat diseases because they are substrates of these efflux pumps either by affecting the pharmacokinetics of drugs in the body or by limiting accumulation in target cells such as cancer cells."
SBFM reports that Adva-27a can overcome two of these xenobiotic pumps - multidrug resistant transporter proteins MDR1 and MRP1, which facilitate multidrug resistance, and as the NIH article notes, MDR1 in particular has become the most studied gene in the field of multidrug resistance.
In terms of gauging the potential market opportunity for Adva-27a for use in the treatment of breast cancer, Roche's Herceptin® reached $5.3 billion a year in sales in 2011. Herceptin® is approved for the treatment of early-stage breast cancer that is Human Epidermal growth factor Receptor 2-positive (HER2+), which the National Cancer Institute estimates represents only 15% - 20% of breast cancer patients. The American Cancer Society estimates that in the U.S. alone, there will be 229,060 new cases of breast cancer diagnosed in 2012, with 39,920 deaths from breast cancer during the year. Given that Herceptin® revenue grew by 9% in 2011 and has risen over 30% since 2006, it seems clear there is a very significant market opportunity for a drug that is effective for the non-HER2+ breast cancer population, which represents a significant majority of breast cancer patients.
As reference for the potential market opportunity for Adva-27a for treatment of small-cell lung cancer, the American Cancer Society estimates there will be 226,160 new cases of lung and bronchus cancer in the U.S. in 2012, with an estimated 160,340 deaths. The National Cancer Institute (NCI) estimates that small-cell lung cancer (SCLC) accounts for approximately 15% of bronchogenic carcinomas. While etoposide, now available as a generic, is used in combination with other medications to treat SCLC, the NCI addresses the challenge and urgency of developing a more effective treatment for SCLC, noting that:
"Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory despite improvements in diagnosis and therapy made during the past 25 years. Without treatment, SCLC has the most aggressive clinical course of any type of pulmonary tumor, with median survival from diagnosis of only 2 to 4 months."
"For most patients with small cell lung cancer, current treatments do not cure the cancer. If lung cancer is found, patients should think about taking part in one of the many clinical trials being done to improve treatment. Clinical trials are taking place in most parts of the country for patients with all stages of small cell lung cancer."
In a recent interview, SBFM CFO Camile Sebaaly noted that the Company expects the first clinical trial of Adva-27a will be done on breast cancer volunteers at Jewish General Hospital. As the Company continues to do the work and raise the capital necessary to bring its drug to market, Mr. Sebaaly stated that the Company expects that if FDA approval is obtained, SBFM may have a similar sales profile to other important cancer drugs that have reached $1 billion in sales within 2 years of FDA approval.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly 20 years of capital markets experience providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. In addition to his work with Murphy Analytics, Mr. Murphy also serves as a consultant to a municipal derivatives advisory firm. Mr. Murphy is an alumnus of the University of Notre Dame (1991), with an undergraduate degree in Economics, and earned a Masters Degree in Finance from St. Louis University in 1997. Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St. Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. The views expressed herein are based upon the author's analysis of the issuer's public disclosures, and assumes both their accuracy and completeness. The opinions and statements included herein are based on sources (including the companies discussed and public sources) believed to be reliable and in good faith, but no representation or warranty, express or implied, is made as to their accuracy, completeness or correctness. The author has not independently verified the information contained herein. This information is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. You should review a complete information package on all companies, which should include, but not be limited to, the Company's annual report, quarterly reports, press releases and all regulatory filings. The foregoing discussion contains statements which are based on current expectations, estimates and projections, and differences from such expectations, estimates and projections can be expected. The author, Patrick Murphy, was compensated $510 by InvestorIdeas.com for writing this article. Murphy does not own shares of any of the companies mentioned in this article. Mr. Murphy's research firm, Murphy Analytics, may be engaged for the provision of a research report on the Company in the future.
About Sunshine Biopharma Inc. (OTCBB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, including biotech and pharma stocks. Visit the biotech portal within Investor Ideas: www.biotechindustrystocks.com
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for the free investor news and biotech stock alerts
Visit the SBFM profile http://www.investorideas.com/CO/SBFM/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: A third party on behalf of SBFM compensated Investorideas.com for news release publishing and distribution: one hundred thousand 144 shares for three months starting June 26 th/
Patrick Murphy was compensated five hundred dollars for the CFA commentary article
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Friday, July 27, 2012

Healthcare and Medical Stock; Comprehensive Care (OTC:CHCR) Expects $18 Million in Revenue and Profitability for Second Quarter

TAMPA, Fla. - July 27, 2012 (Investorideas.com newswire) - Healthcare stock news: Comprehensive Care Corporation (OTCBB: CHCR) reported in late June that it expects to report a profit for the second quarter of 2012, with revenues for the quarter of approximately $18 million. Revenues for the same quarter in 2011 were $18.6 million. However, during that quarter, the Company posted a loss of $4 million.

Commenting on the expected results for the quarter, Robert J. Landis, CompCare's Chief Financial Officer, stated: "The Company is particularly excited about our second quarter expected results since, if realized, it will be the first time in many years that the Company has been able to post a profit for two consecutive quarters. The improvement in results from the second quarter of 2011 to the second quarter of 2012, we believe, is primarily attributable to our Pharmacy Management Program which is now achieving traction and our cost reduction efforts to streamline our internal systems. Part of the shift in the pharmacy program occurred from our establishing Company-owned clinics in areas where we experience high patient utilization and cost. The clinics have the effect of reducing those costs and providing us with a greater opportunity to directly service the needs of the patients. Based on our best current available information, for example, the Company expects to realize a profit in its at-risk pharmacy operations in April, and this trend continues in May where preliminary numbers indicate an increase profit in the Company's at-risk pharmacy operations. While there can be no assurances that this trend will continue or that there might not be subsequent positive or negative adjustments to the April and May results, the upward trend is what we were looking for since we believe that it indicates the viability of the overall program. Other aspects of the Pharmacy Management Program are in the process of being implemented and will occur shortly."
Mr. Landis continued, "Another aspect of the Pharmacy Management Program that contributed to a successful second quarter was the signing of a Third Amendment (the "Amendment") to a material agreement with one of our existing, at-risk pharmacy clients. As a result of the Amendment, the Company received a $2.2 million, retroactive, cash adjustment to pharmacy prescriptions, which were originally charged to the Company. Additionally, the Amendment shifts the financial responsibility for a significant number of prescriptions from the Company to the client for the remainder of 2012. We expect this financial responsibility shift to further reduce the Company's pharmacy expenses throughout the year, and although there can be no guarantees that these expectations will be achieved, we expect the shift to further enhance the Company's profitability in its pharmacy operations for the remainder of 2012."
"Additionally, we were able to implement administrative, cost-saving measures that also contributed to a profitable second quarter," Mr. Landis said.
Revenue and other financial estimates contained in this press release have not been audited or reviewed by the Company's independent auditors, and accordingly they express no opinion or other form of assurance as to this information. The Company provides no assurance that these preliminary results, future expectations or assumptions will be met for the second quarter or fiscal year 2012. The Amendment addresses a number of other aspects of the Company's business with its client. A complete copy of the Amendment has been filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
About CompCare
Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States . Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release, including but not limited to our expected profitability in the second quarter of 2012, the continued implementation of our Pharmacy Management Program, the impact of the financial responsibility shift with one of our existing, at-risk pharmacy clients, our ability to increase margins and to obtain sustainable profitability, our ability to reduce overhead and implement further cost savings, our ability to further improve the Company's performance, the outcome of our business strategy, our ability to expand our pharmacy management program with higher profit margins, and our ability to reduce pharmacy expenses throughout the year are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new and existing business, our ability to expand and manage our provider network, the profitability, if any, of our recently acquired or previously existing capitated contracts, the costs incurred in seeking new contracts, the loss or termination of any existing contract, increases or variations in cost of care, seasonality, the Company's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
949.707.5365
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk. Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Biotech Stock Alert; Aethlon Medical (OTCBB: AEMD) Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors

SAN DIEGO - July 27, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the appointment of Thomas V. Wornham and Philip A. Ward to its board of directors. "We are honored to have Tom and Phil join our board. Their wealth of business experience will be instrumental in guiding the future growth and achievement of our organization," stated Aethlon Chairman & CEO Jim Joyce.

Mr. Wornham recently retired as Executive Vice President & Regional Manager at Wells Fargo Bank in San Diego, representing the culmination of an exemplary career that spanned three decades. At Wells Fargo, Tom's team provided financial solutions to diverse industry organizations whose annual revenues ranged between $10 million to $1 billion dollars. Included among these organizations were public and private life science, biotechnology and medical device companies located throughout San Diego, Imperial, and Southern Riverside Counties. Mr. Wornham is also an active civic leader. He is currently Vice Chairman of the San Diego Water Authority and the past Chairman of the San Diego Regional Chamber of Commerce, The Century Club of San Diego, and the San Diego Regional Economic Development Corporation. Mr. Wornham graduated from University of California Berkeley, with a BA Political Science.
"This is a tremendous opportunity for me to work with Jim and his team," stated Mr. Wornham. "I am excited to be part of a group committed to developing technology that I hope will improve the quality of peoples lives."
Mr. Ward is the former Chairman and CEO, Bignell-Ward-Bignell Corporation; former President and CEO, Hawk Financial Services Corporation, A premium finance company; Former Executive Director and COO of Investments, Golden Eagle Insurance Corporation, a property and casualty California insurance company; and former Executive Vice President and COO Finance at Big Bear Supermarkets, where he was also in charge of acquisitions, as well as leasing and sales of all operating units and real properties.
"I believe in the vision of Aethlon Medical and I look forward to contributing my business acumen to the benefit of shareholders," stated Mr. Ward.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
All financial disclosures, anticipated revenue recognition amounts and other information related to the financial results and operations of the Company set forth above are unaudited and are subject to year-end audit adjustments and footnote disclosures.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Healthcare Stock To Watch: Comprehensive Care (OTCBB: CHCR)

New York, NY - July 27, 2012 (Investorideas.com newswire) - Healthcare stock spotlight at Investorideas.com: InvestorIdeas.com, a global investor research portal for independent investors, releases a company snapshot for microcap Healthcare Stock, Comprehensive Care Corporation (OTCBB: CHCR). The small OTC Company recently made headlines reporting that Florida Trend magazine has ranked CompCare one of the top three big movers among publicly-traded companies in Florida.
Yesterday’s trading saw the Company trade up over 6%. The 52 week range is $ 0.10 - 0.30. The stock has just fewer than 60 Million shares outstanding and a float of just over 15 Million shares.
Investorideas.com Newswire What the analysts say:
Research from SmallCaps.Us and Breakdown and Highlights on CHCR
"Comprehensive Care Corporation (CompCare) provides managed care services in the behavioral health, substance abuse, and psychotropic pharmacy management fields to Medicare, Medicaid, Children's Health Insurance Programs and other commercial health plans.

Regional health plans, which typically don't have their own behavioral health network, will often contract with a Managed Behavioral Healthcare Organization (MBHO) like CompCare, to obtain access to behavioral healthcare professionals, claims processing, case management, better-integrated behavioral healthcare, and psychotropic pharmacy management services.
Although Comprehensive Care was established in 1969, its attractiveness today is an in-progress turnaround that started in 2009 when the current management team took a controlling position in the Company.
The first thing the new management did was get rid of money-loosing contracts. As a result, revenues dropped from over $35 million in 2008 to approximately $14 million in 2009. Next, management members invested approximately $20 to restructure the Company.
They revamped the IT infrastructure and transitioned the Company from processing claims manually, to processing them electronically at a much lower cost. They streamlined operations and expanded their service provider network from 10,000 healthcare participants in 25 states to 35,000 healthcare participants in 46 states, Puerto Rico and theDistrict of Columbia.
All these efforts beared fruit, as revenues quintupled to $71 million in fiscal year 2011, up from $14 million in 2009.
In 2012, the Company is focusing on digesting all its revenue growth and returning to profitability. So far it has been very successful in doing so. In the first quarter of 2012, earnings almost doubled to $80,000, compared with $41,000 in the same period last year. And for the second quarter, which ended a few days ago, the management expects to be profitable whereas it posted a loss of almost $4 million in the second quarter of 2011.
Moreover, because the behavioral healthcare services industry is very price competitive, the Company sought and found a way to get into the higher margin commercial pharmaceuticals delivery market. CompCare contracts with PBMs to obtain the lowest possible prices for both branded and generic drugs, which results in significant cost savings for CompCare's clients." Source and Opinion of: * http://www.smallcaps.us
About CompCare (OTCBB: CHCR) Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Profile page at Investorideas.com
http://www.investorideas.com/CO/CHCR/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
All investment involves risk . The opinion of smallcaps.us is not the opinion or research of Investorideas.com Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411

Thursday, July 26, 2012

Tech Stock Trading News Alert; Big Moves for Microtechnology Stock (NASDAQ:ESIO) on Earnings News

New York, NY - July 26, 2012 (InvestorIdeas.com Newswire) Investor Ideas, www.InvestorIdeas.com, a global investor research portal for independent investors, issues a tech stock trading alert for Electro Scientific Industries Inc. (NasdaqGS :ESIO), trading up at $13.28, gaining $2.50 or 23.19% as of 11:45AM EDT. The Company reported first quarter earnings yesterday on the bell.
Revenue in the first quarter was $59.0 million, compared to $45.5 million in the fourth quarter of 2012 and $77.0 million in the first quarter of last fiscal year. On a GAAP basis, net loss was $0.9 million or $0.03 per share, compared to a loss of $7.7 million or $0.26 per share in the prior quarter. On a non-GAAP basis, first quarter net income was $1.9 million or $0.06 per diluted share, compared to a loss of $1.9 million or $0.06 per share in the fourth quarter of fiscal 2012 and income of $7.9 million or $0.27 per diluted share in the first quarter of fiscal 2012.
Investorideas.com Newswire About ESI
ESI is a leading supplier of innovative, laser-based manufacturing solutions for the microtechnology industry. Our systems enable precise structuring and testing of micron to submicron features in electronic devices, semiconductors, LEDs and other high-value components. We partner with our customers to make breakthrough technologies possible in the microelectronics, semiconductor and other emerging industries. Founded in 1944, ESI is headquartered in Portland, Ore., with global operations from the Pacific Northwest to the Pacific Rim. www.esi.com.
About Investorideas.com

InvestorIdeas.com is a leader in investor stock research with a focus on energy and water. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Healthcare Stock Investor News: Comprehensive Care (OTCBB:CHCR) Named Among Top Florida Public Companies

TAMPA, Fla. - July 26, 2012 (Investorideas.com newswire) Healthcare Stock news: Comprehensive Care Corporation ("CompCare" or the "Company") (OTC BB: CHCR) is pleased to announce that Florida Trend magazine has ranked CompCare one of the top three big movers among publicly-traded companies in Florida.

Florida Trend has been a key source of business news, insight, forecast and trends since 1958. Its circulation includes the State's top business executives, government officials and civic leaders.
"I am extremely proud that CompCare has been recognized as one of the top three big movers among publicly-traded companies in Florida by such a well-respected publication. This independent third-party acknowledgment validates our employees' hard work and dedication as well as demonstrates our commitment as a company to achieving results. We look forward to additional accomplishments, such as our new Pharmacy Management Program, which we believe will play a key role in our future. This program is designed to reduce the cost of our clients' pharmacy spend by up to 10 percent. We will continue to work to achieve positive results so that we place even higher in Florida Trend's next survey," said Clark A. Marcus, Chairman and CEO.
About CompCare
Established in 1969, CompCare provides behavioral health, substance abuse and employee assistance programs for governmental agencies, managed care companies and employer groups throughout the United States . Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches to behavioral health that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release, including but not limited to our expected positive accomplishments in the future, our ability to expand our pharmacy management program with higher profit margins, our ability to reduce our clients' pharmacy spend by 10 percent, our ability to further improve the Company's performance and maintain positive trends, and the outcome of our business strategy throughout the year are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the Company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new and existing business, our ability to expand and manage our provider network, the profitability, if any, of our recently acquired or previously existing capitated contracts, the costs incurred in seeking new contracts, the loss or termination of any existing contract, increases or variations in cost of care, seasonality, the Company's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which is available on its website at www.sec.gov.
Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584
Published at Investorideas.com Newswire
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure: Investorideas.com is compensated for publishing and distributing news for CHCR: four thousand for one month by third party IR firm
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Wednesday, July 25, 2012

Clean Energy Stock News Alert: Clean Wind Energy Tower (OTC: CWET) Trades up on Volume Following Patent News

Renewable Energy Stock Alert: Clean Wind Energy Tower (OTC: CWET) Trades up on Volume Following Patent News

New York, NY – July 25, 2012 - Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in renewable energy stock research, releases a trading alert for
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading up at $ 0.0650, up   0.0070(12.07%) on over 800,000 shares following recent patent news.

The Company announced the publishing of its patent titled Efficient Energy Conversion Devices & Methods (U.S. Pat. No. 8,120,191) by the United States Patent and Trademark Office.

The patent covers specific aspects of deploying multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as providing a consistency of power output during any deviations in wind speed. The Company considers this patent to be a "Core Patent" providing a significant barrier to entry for any potential competitor.





Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp

Research renewable energy stocks- directory of over 1400 green stocks http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Disclaimer/ Disclosure: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Disclosure: Investorideas.com is compensated by CWET one thousand per month and owns 100,000 144 shares for news publishing and distribution of content.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

For more information about Investorideas.com contact:
800.665.0411